As the stimulus funds for science grants begin to be handed out and the healthcare bill continues moving on its probably getting close to the time for the gene sequencing business at agilent to begin picking up in addition to its chip and communication businesses. Life sciences has been an under performing sector and as we head into the next several quarters it could be a valuable addition to growth estimates.

http://www.genomeweb.com/blog/what-does-...

http://www.researchandmarkets.com/report...

http://www.ncbi.nlm.nih.gov:80/pmc/artic...

http://www.sciencedirect.com/science?_ob...

Personalized medications to optomize costs and benefits and the need to increase crop yields and protect against disease all becoming more important as the world moves forward and there are larger middle classes demanding higher standards of living.